DNLI
Price
$20.86
Change
+$1.08 (+5.46%)
Updated
Mar 1, 6:59 PM EST
61 days until earnings call
NTLA
Price
$32.66
Change
+$0.54 (+1.68%)
Updated
Mar 1, 6:59 PM EST
61 days until earnings call
Ad is loading...

Compare predictions DNLI vs NTLA

Header iconDNLI vs NTLA Comparison
Open Charts DNLI vs NTLABanner chart's image
Denali Therapeutics
Price$20.86
Change+$1.08 (+5.46%)
Volume$746.66K
CapitalizationN/A
Intellia Therapeutics
Price$32.66
Change+$0.54 (+1.68%)
Volume$1.18M
CapitalizationN/A
View a ticker or compare two or three
DNLI vs NTLA Comparison Chart

Loading...

DNLIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NTLADaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
DNLI vs. NTLA commentary
Mar 02, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongSell and NTLA is a StrongBuy.

COMPARISON
Comparison
Mar 02, 2024
Stock price -- (DNLI: $20.86 vs. NTLA: $32.66)
Brand notoriety: DNLI and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 65% vs. NTLA: 74%
Market capitalization -- DNLI: $2.73B vs. NTLA: $3.09B
DNLI [@Biotechnology] is valued at $2.73B. NTLA’s [@Biotechnology] market capitalization is $3.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $541.24B to $0. The average market capitalization across the [@Biotechnology] industry is $2.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while NTLA’s TA Score has 6 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 4 bearish.
  • NTLA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +23.21% price change this week, while NTLA (@Biotechnology) price change was +25.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was +20.20%, and the average quarterly price growth was +48.09%.

Reported Earning Dates

DNLI is expected to report earnings on May 02, 2024.

NTLA is expected to report earnings on May 02, 2024.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for DNLI with price predictions.
OPEN
A.I.dvisor published
a Summary for NTLA with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
NTLA($3.09B) has a higher market cap than DNLI($2.73B). NTLA YTD gains are higher at: 7.117 vs. DNLI (-2.796). DNLI has higher annual earnings (EBITDA): -150.83M vs. NTLA (-506.32M). DNLI has more cash in the bank: 1.11B vs. NTLA (912M). DNLI has less debt than NTLA: DNLI (53.9M) vs NTLA (115M). DNLI has higher revenues than NTLA: DNLI (341M) vs NTLA (36.3M).
DNLINTLADNLI / NTLA
Capitalization2.73B3.09B89%
EBITDA-150.83M-506.32M30%
Gain YTD-2.7967.117-39%
P/E Ratio62.89N/A-
Revenue341M36.3M939%
Total Cash1.11B912M122%
Total Debt53.9M115M47%
FUNDAMENTALS RATINGS
DNLI vs NTLA: Fundamental Ratings
DNLI
NTLA
OUTLOOK RATING
1..100
2312
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
52
Fair valued
PROFIT vs RISK RATING
1..100
9380
SMR RATING
1..100
9096
PRICE GROWTH RATING
1..100
5050
P/E GROWTH RATING
1..100
96100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (52) in the Biotechnology industry is in the same range as DNLI (81). This means that NTLA’s stock grew similarly to DNLI’s over the last 12 months.

NTLA's Profit vs Risk Rating (80) in the Biotechnology industry is in the same range as DNLI (93). This means that NTLA’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (90) in the Biotechnology industry is in the same range as NTLA (96). This means that DNLI’s stock grew similarly to NTLA’s over the last 12 months.

DNLI's Price Growth Rating (50) in the Biotechnology industry is in the same range as NTLA (50). This means that DNLI’s stock grew similarly to NTLA’s over the last 12 months.

DNLI's P/E Growth Rating (96) in the Biotechnology industry is in the same range as NTLA (100). This means that DNLI’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLINTLA
RSI
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 8 days ago
79%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 10 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
80%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
DNLIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NTLADaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MPASX9.81N/A
N/A
MassMutual Strat Emerg Mkts A
HIOCX14.73N/A
N/A
Hartford International Opportunities C
CGFAX67.83N/A
N/A
American Funds Growth Fund of Amer 529A
PAGLX38.19N/A
N/A
T. Rowe Price Global Growth Stock Adv
FLAPX17.13N/A
N/A
Fidelity Flex Mid Cap Index